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Uremic lung: new insights  
into a forgotten condition
Paul J. Scheel1, Manchang Liu1 and Hamid Rabb1
The high mortality rate of acute kidney injury (AKI) despite advances in 
dialysis led to a renewed appreciation of the impact of AKI on distant 
organ dysfunction. Mechanistic studies demonstrated that AKI induces 
increased lung vascular permeability, soluble and cellular inflammation, 
and dysregulated salt and water channels. AKI also affects the brain, heart, 
liver, bone marrow, and gastrointestinal tract. Klein et al. now demonstrate 
that interleukin-6 is a direct mediator of AKI-induced lung changes.
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The modern era of the study of the patho-
physiology of acute renal failure (currently 
referred to as acute kidney injury, AKI) 
began with the publication of the land-
mark observations of Bywaters and Beall1 
in the early 1940s with their description 
of the physiologic changes observed in 
soldiers suffering from AKI attributed to 
crush injury. Unfortunately, only support-
ive therapy was available, and the mortality 
in this population was greater than 90%. 
In the 1950s it was identified that the lung 
can also be injured during AKI, with these 
patients manifesting abnormal chest X-rays 
postulated to be secondary to “increased 
permeability of congested pulmonary 
capillaries.”2 These lung changes were also 
identified in chronic kidney disease, and 
dubbed ‘uremic lung.’ With the introduc-
tion of dialysis in the 1950s, the mortality 
rates associated with AKI decreased to 
50%–60%. With fluid removal by dialysis, 
many believed that ‘uremic lung’ was no 
longer a real entity, that the lung changes 
observed during kidney dysfunction were 
entirely due to increased effective blood 
volume, and that dialysis was the answer 
for patients with AKI. Unfortunately, over 
the past 50 years there has been minimal 
improvement in this high mortality rate 
despite improvements in dialysis technol-
ogy and advances in supportive care.
AKI still remains a common condition 
in hospitalized patients, especially those 
in an intensive care unit (ICU) setting. A 
multicenter, multinational study found 
that 6% of ICU patients had severe enough 
AKI to require renal replacement therapy.3 
While newer studies have confirmed the 
high rates of renal injury in an ICU set-
ting, these have also alerted the renal com-
munity to previously unforeseen effects of 
mild to moderate kidney injury — those of 
increased mortality with mild to moder-
ate elevations in serum creatinine. Patients 
with a 25% increase in serum creatinine 
secondary to radiocontrast injection had 
a fivefold increase in hospital mortal-
ity.4 In an analysis of hospital records of 
19,982 adult patients, a more than 0.5 
mg/dl increase in serum creatinine was 
associated with a 6.5-fold increase in the 
odds of death.5 Though most believed that 
the high mortality rate was from patients 
dying ‘with renal disease,’ increasing data 
now support that patients are dying ‘from 
renal disease.’
How does one explain the relationship 
between AKI and escalating mortality? Is 
AKI merely an indicator of severe organ 
injury, and dialysis only changing the 
cause of death rather than incidence and 
timing? Does AKI directly, either through 
direct kidney injury or inability to clear 
toxic substances, lead to distant organ dys-
function that in turn predisposes to death? 
To evaluate whether AKI directly effects 
distant organ function, and whether the 
entity called ‘uremic lung’ is indeed real, 
mechanistic studies with new tools have 
been performed in rodents during AKI. 
AKI increased pulmonary vascular albu-
min permeability, erythrocyte sludging 
in lung capillaries, and interstitial edema, 
even when animals did not acutely gain 
total body fluids.6 Furthermore, interven-
ing by dampening systemic macrophage 
function partially attenuated lung changes 
after AKI. The increased lung interstitial 
edema was associated with dysregulated 
lung salt and water transporters, notably 
ENaC, Na, K-ATPase, and aquaporin-5.7 
The lung changes after AKI were found 
to start early and could be attenuated with 
α-melanocyte-stimulating hormone, a 
broad anti-inflammatory agent.8 Comorbid 
conditions such as sickle-cell disease accen-
tuated AKI effects on the lung.9 Detailed 
genomic analysis followed by polymerase 
chain reaction and protein studies led to the 
prediction that multiple pathways, includ-
ing interleukin-6 (IL-6), IL-10, endothelin, 
and serum amyloid 3, could mediate AKI-
induced lung dysfunction.10,11 AKI leads 
to abnormalities in many other organs 
besides the lung (Figure 1). AKI has been 
reported to increase cardiac apoptosis and 
production of IL-1 and tumor necrosis fac-
tor.12 Given that severe AKI is well known 
to cause uremic encephalopathy, a classic 
indication to initiate dialysis, the effects of 
AKI on the brain have been studied exper-
imentally. In mice, AKI led to increased 
expression of glial fibrillary acidic protein 
(a marker of inflammation) in astrocytes in 
the cortex and corpus callosum, activation 
of microglia (brain macrophages), increased 
vascular permeability to blood albumin, 
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increased levels of the pro inflammatory 
chemokines keratinocyte-derived chemo-
attractant and granular colony-stimulating 
factor in the cerebral cortex and hippocam-
pus, and decreased locomotor activity.13
Klein et al.14 (this issue) have now fur-
ther explored pathways and mechanisms 
by which AKI leads to lung changes in a 
mouse model. They confirm previous 
results showing that AKI leads to increased 
lung vascular permeability and both cellu-
lar and soluble inflammation in the lung, 
and that lung dysfunction begins within 
hours. Additionally, they demonstrate that 
IL-6 is a direct mediator of AKI-induced 
increase in vascular permeability, leuko-
cyte trafficking, and increased edema. 
This is elegantly proven with comple-
mentary in vivo approaches — use of IL-
6-deficient mice, IL-6-blocking antibody, 
and administration of IL-6 protein directly 
into wild-type mice. They use an impor-
tant control, bilateral nephrectomy, and 
demonstrate that IL-6 still mediates lung 
changes in the absence of kidneys; thus 
the kidney is not an essential source of the 
deleterious IL-6. Another important new 
finding is the linkage of IL-6 effects on the 
lung with keratinocyte-derived chemok-
ine (KC). KC is a CXC chemokine that is 
structurally homologous to rat cytokine-
induced neutrophil chemoattractant and 
human growth-related oncogene-α, which 
regulates neutrophil trafficking and is an 
early biomarker of AKI.15 KC rapidly 
increases in mouse lung after AKI, and 
this rise is blunted with manipulations in 
IL-6. As another chemokine, macrophage 
inflammatory protein 2, was unaffected by 
IL-6 interventions, a degree of specificity 
to the IL-6–KC pathway was postulated. A 
number of other interesting questions arise 
from these data. Given that most patients 
are seen after the initial kidney injury, the 
lung effects of starting IL-6 antibody after 
different reperfusion times, rather than 
only before treatment, would have been 
useful to study. The lung, like the kidney, 
has regional heterogeneity; thus, did AKI 
have uniform or localized effects on the 
lung? What cells produce IL-6 after AKI, 
and what cells in the lung were targets of 
IL-6? What are the mechanisms by which 
IL-6 leads to alterations in microvascular 
inflammation and permeability? On a tech-
nical note, it is interesting that 22 minutes 
of kidney ischemia led to AKI and distant 
organ changes in this laboratory, whereas 
in most other laboratories, longer ischemic 
times are needed to induce a rise in serum 
creatinine in mice. Differences among lab-
oratories, including those in temperature 
regulation, fluids, and perhaps even altitude 
in this case (these studies were performed 
in Denver, Colorado, one mile above sea 
level), could have effects. This underscores 
the importance of tight internal controls 
and careful descriptions of how the study 
was performed.
Studies in rodents are crucial to iden-
tify mechanisms and to examine safety 
before human studies are conducted, 
and it is important to know whether the 
current findings are applicable to larger 
mammal models and, ultimately, humans. 
It is well established that injury to the 
gut or limb alters the lung, but given the 
important clearance function of the kid-
ney, what distinguishes the effects of AKI 
on the lung from the effects of injury to 
other organs? What other soluble factors 
besides IL-6 mediate AKI-induced distant 
organ injury, and what is the role of other 
non-inflammatory pathways — such as 
neural arcs? Though we assume that AKI 
only leads to worsening of distant organ 
function, this is probably simplistic: AKI 
in mice reduced the decline in peripheral 
blood oxygenation normally caused by 
lung injury induced by acid aspiration and 
injurious mechanical ventilation.16
How can we use these studies to 
decrease the high mortality and morbid-
ity rate in patients with AKI? Given that 
increased dosing of dialysis from three 
to five to six times per week is unlikely 
to improve mortality during AKI,17 what 
other strategies can be designed to better 
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figure 1 | AKI-induced distant organ effects. AKI leads to changes in distant organs, including 
brain, lungs, heart, liver, gastrointestinal tract, and bone marrow. Changes have been described in 
organ function, microvascular inflammation and coagulation, cell apoptosis, transporter activity, 
oxidative stress, and transcriptional responses. Abbreviations: AKI, acute kidney injury; G-CSF, 
granular colony-stimulating factor; GFAP, glial fibrillary acidic protein; GSH, glutathione; IL-1, 
interleukin-1; KC, keratinocyte-derived chemokine; TNF-α, tumor necrosis factor-α.
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clear AKI-induced distant organ toxins? 
Earlier initiation of dialysis? Continu-
ous dialysis over intermittent? Improved 
membranes? Novel dialysis approaches, 
such as the renal assist device? Pharma-
cologic approaches to block deleteri-
ous pathways induced by AKI? A major 
opportunity clearly exists to improve 
our care of AKI patients, and studies on 
complex inter-organ cross talk will guide 
rational interventions in this common, 
often catastrophic, syndrome.
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Renin–angiotensin system 
blockade and diabetes:  
moving the adipose organ from 
the periphery to the center
Oliver Lenz1 and Alessia Fornoni1,2
Lee et al. report that an angiotensin II type 1 receptor blocker (ARB) 
improved glucose intolerance in OLETF rats, an experimental model of 
type 2 diabetes. ARB treatment resulted in modulation of the adipose 
tissue, leading to an increased number of small, differentiated adipocytes 
able to produce more adiponectin and less monocyte chemoattractant 
protein-1 and plasminogen activator inhibitor-1. This supports the 
relevance of the functional interplay between adipose tissue and the 
renin–angiotensin system in states of insulin resistance.
Kidney International (2008) 74, 851–853. doi:10.1038/ki.2008.391
A large body of literature suggests that 
renin–angiotensin system (RAS) block-
ade with either an angiotensin-converting 
enzyme inhibitor or an angiotensin recep-
tor blocker (ARB) will prevent new-onset 
type 2 diabetes.1 Two receptors for angio-
tensin II have been described in humans, 
the angiotensin II type 1 (AT1) and type 2 
(AT2) receptors. Among them, the AT1 
receptor seems to be primarily responsible 
for the metabolic effect of RAS blockade.2 
In fact, the AT1 and AT2 receptors may 
have antagonistic activities on glucose 
uptake and cell differentiation in adipose 
tissue, as suggested by studies performed 
in AT2-null mice.3 How RAS blockade 
leads to a diminished incidence of type 
2 diabetes remains to be fully elucidated. 
The following mechanisms are being 
investigated (Figure 1): upregulation of 
muscle glucose uptake via modulation 
of glucose transporter-4 (GLUT4) and 
blood flow;4 improvement of pancreatic 
β-cell function;5 modulation of hormonal 
responses from adipose tissue;2 decreased 
hepatic gluconeogenesis and increased 
free fatty acid oxidation;6 improvement 
of endothelial function through down-
regulation of NADPH oxidase;2 direct 
stimulation of insulin signaling at multi-
ple levels;7 and direct regulation of per-
oxisome proliferator-activated receptor-γ 
(PPARγ) by selected ARBs, such as tel-
misartan and irbesartan.8 Experimental 
data suggest that RAS-blocking agents 
that act on more than one pathway might 
be more effective for the prevention of 
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